Abstract: ASP2215 (Gilteritinib) is a highly potent, second-generation, Type I tyrosine kinase inhibitor targeting both FMS-like tyrosine kinase 3 (FLT3) and AXL. While currently approved for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), its therapeutic role is rapidly expanding into the frontline setting for newly diagnosed AML. This review synthesizes current literature on gilteritinib's pharmacological activity, molecular mechanisms, and structure-activity relationships, with a specific focus on newly diagnosed AML. Clinical trials evaluating gilteritinib in combination with intensive induction chemotherapy ("7+3" regimen) and novel triplet therapies (with venetoclax and hypomethylating agents) have demonstrated remarkable complete remission rates. However, limitations such as the failure to improve overall survival in the LACEWING trial and the emergence of secondary resistance mutations (e.g., Ras/MAPK pathway and FLT3-F691L) highlight ongoing clinical challenges. Future perspectives emphasize optimizing combination strategies and maintenance therapies to achieve durable remissions in newly diagnosed FLT3-mutated AML.
1. Introduction
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the rapid proliferation of immature myeloid blasts. Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene are among the most common genomic alterations in AML, occurring in approximately 30% of newly diagnosed patients [33]. These mutations primarily present as internal tandem duplications (ITD) or tyrosine kinase domain (TKD) point mutations, both of which lead to constitutive kinase activation, highly proliferative disease, and poor clinical outcomes [33].
Gilteritinib (ASP2215) is a rationally designed, second-generation FLT3 inhibitor [9]. Following its success in the phase III ADMIRAL trial, which led to its approval for relapsed/refractory (R/R) FLT3-mutated AML, research has increasingly focused on incorporating gilteritinib into frontline therapies for newly diagnosed AML [1]. This review explores the application of gilteritinib in newly diagnosed AML, detailing its pharmacological efficacy, mechanisms of action, structural advantages, and future therapeutic potential.
2. Pharmacological Activity
The pharmacological activity of gilteritinib in newly diagnosed AML has been evaluated across various combination regimens to maximize frontline efficacy:
Combination with Intensive Chemotherapy: In a phase I/II dose-escalation study, gilteritinib was combined with standard "7+3" induction and consolidation chemotherapy in newly diagnosed FLT3-mutated AML patients. The maximum tolerated dose was established at 120 mg/day. The composite complete remission (CR) rate was exceptionally high, reaching 100% in patients receiving gilteritinib on schedule 1 (days 4-17) and 81.8% on schedule 2 (days 8-21) [1].
Combination with Hypomethylating Agents (HMAs): For patients ineligible for intensive chemotherapy, the phase III LACEWING trial evaluated gilteritinib combined with azacitidine versus azacitidine alone. Although the combination yielded significantly higher composite CR rates, it failed to improve overall survival (OS) compared to monotherapy, leading to the early termination of the study for futility [1].
Triplet Therapies: Highly promising results have emerged from triplet combinations involving gilteritinib, venetoclax, and HMAs (azacitidine or decitabine). A phase I/II trial evaluating azacitidine, venetoclax, and gilteritinib reported a 100% CR/CRi (complete remission with incomplete hematologic recovery) rate in newly diagnosed FLT3-mutated AML patients [1]. Similarly, a triplet regimen of decitabine, venetoclax, and gilteritinib achieved a composite CR rate of 88% in newly diagnosed patients unfit for intensive induction, with 100% of responders achieving FLT3-PCR negativity [55] [60].
3. Molecular Mechanism of Action
Gilteritinib is a dual inhibitor of FLT3 and AXL kinases [9]. AXL is an oncogenic tyrosine kinase frequently overexpressed in AML that facilitates FLT3 activation, serving as a known mechanism of resistance to other FLT3 inhibitors [9]. By inhibiting both targets, gilteritinib effectively suppresses FLT3 phosphorylation and downstream signaling pathways (such as JAK/STAT, PI3K/AKT, and RAS/MEK/ERK) [33].
Additionally, gilteritinib strongly inhibits anaplastic lymphoma kinase (ALK) and leukocyte receptor tyrosine kinase (LTK). Crucially, unlike several other FLT3 inhibitors, it does not significantly inhibit c-KIT, which helps spare normal hematopoiesis and reduces severe myelosuppression [9].
Preclinical models demonstrate that when combined with chemotherapy, gilteritinib upregulates cleaved poly (ADP-ribose) polymerase (cPARP), enhancing apoptotic activity. It also downregulates anti-apoptotic proteins, including MCL-1, BCL2L10, and survivin [12]. The downregulation of MCL-1 by gilteritinib is particularly important as it synergistically enhances the apoptotic efficacy of the BCL-2 inhibitor venetoclax [12].
4. Structure-Activity Relationship (SAR)
Gilteritinib is classified as a Type I FLT3 inhibitor. The structural significance of Type I inhibitors lies in their ability to bind to the active conformation of the kinase domain [19]. This structural interaction allows gilteritinib to effectively inhibit both FLT3-ITD mutations and FLT3-TKD point mutations (such as those at the D835 residue) [9] [19]. In contrast, Type II inhibitors (e.g., quizartinib and sorafenib) bind only to the inactive conformation of the kinase and are therefore highly susceptible to resistance conferred by TKD mutations, which stabilize the active kinase conformation [19]. Gilteritinib's rational design thus addresses a major structural limitation of earlier FLT3 inhibitors, providing broad activity against a wider array of resistance-conferring mutations.
5. Current Limitations
Despite its potency, the clinical application of gilteritinib faces several limitations:
Clinical Efficacy in Unfit Patients: As demonstrated by the LACEWING trial, combining gilteritinib with azacitidine did not translate into an overall survival benefit for newly diagnosed patients ineligible for intensive chemotherapy, indicating that dual therapy may be insufficient in this demographic [1].
Adverse Events: Gilteritinib is associated with significant toxicities. Common adverse events include pyrexia, elevated alanine aminotransferase (ALT), and elevated aspartate aminotransferase (AST) [51]. Severe (grade 3-4) adverse events include febrile neutropenia, anemia, and thrombocytopenia [51].
Acquired Resistance: Secondary resistance remains a critical hurdle. The emergence of mutations in the Ras/MAPK pathway (e.g., NRAS and KRAS) can bypass FLT3 inhibition, mediating continued leukemic signaling [39]. Furthermore, the acquisition of the FLT3-F691L "gatekeeper" mutation structurally hinders gilteritinib binding, conferring resistance, though higher doses (>200 mg/day) may partially overcome this [39].
6. Future Perspectives
The future of gilteritinib in newly diagnosed AML lies in optimizing combination regimens and maintenance strategies. Ongoing randomized phase II/III trials are directly comparing gilteritinib to midostaurin in combination with standard induction and consolidation chemotherapy (e.g., NCT03836209) to establish the optimal frontline FLT3 inhibitor [42].
Triplet therapies combining gilteritinib with venetoclax and HMAs represent a highly promising frontier, potentially offering deep and durable remissions for patients unfit for intensive chemotherapy [60]. Additionally, the role of gilteritinib as a maintenance therapy following consolidation (NCT02927262) or allogeneic stem cell transplantation (allo-SCT) (NCT02997202) is being actively investigated to prevent relapse and eradicate minimal residual disease [42]. Finally, combining gilteritinib with other targeted agents, such as immunotherapies (e.g., atezolizumab, NCT03730012), may provide novel avenues to preempt or overcome resistance mechanisms [42].
